VALN News and Press, Valneva SE From 09/16/22

French biotech Valneva ( NASDAQ: VALN ) on Friday said it had agreed to terminate its COVID-19 vaccine drug substance manufacturing agreement with contract development organization IDT Biologika following the suspension of the manufacturing of the shot. The European Commissi...

Summary Bearish sentiment weighed heavily on the biotech industry and Bavarian Nordic A/S. There is reason for optimism given the current opportunities offered by Monkeypox, Ebola and Covid-19. The company is preparing for a new era of high-risk tropical infections and coronav...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis ...

Citing new data from a late-stage study, French biotech Valneva SE ( NASDAQ: VALN ) announced Monday that the company's COVID-19 vaccine as a booster provided similar protection to AstraZeneca's ( AZN ) rival COVID-19 vaccine. The data from the Cov-Compare indicated th...

French vaccine maker Valneva ( NASDAQ: VALN ) announced Thursday that the company initiated the rolling submission of a Biologics License Application (BLA) to the FDA, seeking the U.S. regulatory nod for its single-shot chikungunya vaccine candidate. The BLA aimed at those...

The World Health Organization (WHO) on Thursday recommended VLA2001, the inactivated whole-virus COVID-19 vaccine, developed by French vaccine maker Valneva ( NASDAQ: VALN ) for the prevention of coronavirus disease. The decision follows the WHO’s Strategic Advisory...

Valneva ( NASDAQ: VALN ) ( OTCPK:INRLF ) ( OTC:VNVLF ) said the U.S. Department of Defense (DoD) decided not to exercise the second option year of the contract to get the company's Japanese encephalitis (JE) vaccine Ixiaro. Due to the impact of the COVI...

Valneva ( NASDAQ: VALN ) entered in a new financing program to offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $75.0M of American Depositary Shares, each ADS representing two of the company’s ordinary sh...

Valneva press release ( NASDAQ: VALN ): 1H Net loss of €171.5M Revenue of €93.2M (+96.2% Y/Y). For further details see: Valneva reports 1H results

Valneva ( NASDAQ: VALN ) ( OTCPK:INRLF ) ( OTC:VNVLF ) reduced its FY22 revenue outlook citing reduced demand for its COVID vaccine from the EU member states. COVID-19 vaccine sales in H1 were €3.8M. However, Valneva recorded an operating loss of...